Vernakalant: Difference between revisions

Revision as of 11:55, 9 February 2025

Vernakalant

Vernakalant is a pharmaceutical drug used primarily for the treatment of atrial fibrillation, a common type of irregular heartbeat. It is classified as an antiarrhythmic agent and works by affecting the electrical activity of the heart to restore normal rhythm.

Mechanism of Action

Vernakalant acts by blocking specific ion channels in the heart, particularly the potassium and sodium channels. This action prolongs the refractory period of atrial tissue and slows down the conduction of electrical impulses, which helps to stabilize the heart's rhythm. Unlike other antiarrhythmic drugs, vernakalant has a selective effect on atrial tissue, which reduces the risk of ventricular arrhythmias.

Clinical Use

Vernakalant is administered intravenously and is used for the rapid conversion of recent-onset atrial fibrillation to sinus rhythm. It is particularly effective in patients with atrial fibrillation of less than 7 days duration. The drug is not recommended for patients with severe heart failure or those with significant structural heart disease.

Side Effects

Common side effects of vernakalant include taste disturbances, sneezing, and nausea. More serious side effects can include hypotension, bradycardia, and ventricular arrhythmias. Due to these potential risks, vernakalant should be administered under close medical supervision.

Regulatory Status

Vernakalant has been approved for use in several countries, including those in the European Union and Canada. However, it has not been approved by the United States Food and Drug Administration (FDA) as of the latest updates.

Related Research

Ongoing research is exploring the use of vernakalant in different patient populations and its long-term efficacy and safety. Studies are also investigating its potential use in combination with other antiarrhythmic agents.

Related Pages

References

Camm, A. J., et al. (2011). "Vernakalant: A novel antiarrhythmic agent for the rapid conversion of atrial fibrillation." *Journal of Cardiovascular Electrophysiology*, 22(1), 1-9.
Kowey, P. R., et al. (2009). "Vernakalant: A new approach to the management of atrial fibrillation." *American Heart Journal*, 157(3), 412-419.

@@ Line 1: / Line 1: @@
-'''Vernakalant''' is a medication used to treat [[atrial fibrillation]] and [[atrial flutter]], two common types of abnormal heart rhythm. It is an antiarrhythmic agent that works by blocking certain electrical signals in the heart to stabilize its rhythm.
+== Vernakalant ==
+[[File:Vernakalant.svg|thumb|Chemical structure of Vernakalant]]
+'''Vernakalant''' is a pharmaceutical drug used primarily for the treatment of atrial fibrillation, a common type of irregular heartbeat. It is classified as an antiarrhythmic agent and works by affecting the electrical activity of the heart to restore normal rhythm.
 == Mechanism of Action ==
+Vernakalant acts by blocking specific ion channels in the heart, particularly the potassium and sodium channels. This action prolongs the refractory period of atrial tissue and slows down the conduction of electrical impulses, which helps to stabilize the heart's rhythm. Unlike other antiarrhythmic drugs, vernakalant has a selective effect on atrial tissue, which reduces the risk of ventricular arrhythmias.
-Vernakalant works by selectively blocking [[potassium channels]] in the heart that are active during [[repolarization]], following an electrical impulse. This action prolongs the duration of the [[action potential]], slowing the rate of electrical impulses and thus the heart rate.
+== Clinical Use ==
+Vernakalant is administered intravenously and is used for the rapid conversion of recent-onset atrial fibrillation to sinus rhythm. It is particularly effective in patients with atrial fibrillation of less than 7 days duration. The drug is not recommended for patients with severe heart failure or those with significant structural heart disease.
-== Uses ==
-Vernakalant is used to convert (change) recent-onset atrial fibrillation to normal sinus rhythm. It is used in adults who have had atrial fibrillation for 7 days or less. Vernakalant can also be used in people with atrial fibrillation following heart surgery.
 == Side Effects ==
+Common side effects of vernakalant include taste disturbances, sneezing, and nausea. More serious side effects can include hypotension, bradycardia, and ventricular arrhythmias. Due to these potential risks, vernakalant should be administered under close medical supervision.
-Common side effects of vernakalant include [[dysgeusia]] (taste disturbances), [[sneezing]], [[nausea]], and [[paresthesia]] (tingling or numbness). Serious side effects can include [[arrhythmia]] (irregular heartbeat), [[hypotension]] (low blood pressure), and [[shock]].
+== Regulatory Status ==
+Vernakalant has been approved for use in several countries, including those in the European Union and Canada. However, it has not been approved by the United States Food and Drug Administration (FDA) as of the latest updates.
-== Contraindications ==
+== Related Research ==
+Ongoing research is exploring the use of vernakalant in different patient populations and its long-term efficacy and safety. Studies are also investigating its potential use in combination with other antiarrhythmic agents.
-Vernakalant should not be used in people with severe [[heart failure]], [[hypotension]], or a history of [[Torsades de Pointes]]. It should also not be used in people who have taken certain other medications within the previous 48 hours.
-== See Also ==
+== Related Pages ==
+* [[Atrial fibrillation]]
 * [[Antiarrhythmic agent]]
-* [[Atrial fibrillation]]
-* [[Atrial flutter]]
 * [[Potassium channel]]
+* [[Sodium channel]]
-[[Category:Drugs]]
+== References ==
-[[Category:Cardiology]]
+* Camm, A. J., et al. (2011). "Vernakalant: A novel antiarrhythmic agent for the rapid conversion of atrial fibrillation." *Journal of Cardiovascular Electrophysiology*, 22(1), 1-9.
-[[Category:Pharmacology]]
+* Kowey, P. R., et al. (2009). "Vernakalant: A new approach to the management of atrial fibrillation." *American Heart Journal*, 157(3), 412-419.
-{{stub}}
+[[Category:Antiarrhythmic agents]]